B+
Bull case
30%
Probability
Target price
$17.00
+321.8% vs current
CING
CingulateDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment AIMost likely
B
Base case
50%
Probability
Target price
$9.50
+135.7% vs current
B-
Bear case
20%
Probability
Target price
$4.00
-0.7% vs current
AI sentiment snapshot
Latest data as of 2026-04-10
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+100.0
Score
AI commentary
Recent corporate communications emphasize IP progress (Notice of Allowance) and commercialization preparations, producing a constructive operational tone among investors [#PR-2026-03-18]. The closing of a $12M private placement reduced near-term financing anxiety, supporting modest positive sentiment [#PR-undated]. An 8-K filing confirmed a March 27, 2026 report date, signalling routine disclosure activity without surprise governance items [#8-K-2026-04-02].
RankAlpha Sentiment AI - 2026-04-10
Open full AI memoEvidence flagged
small-cap biotech buy thesis remains too speculative for a standard-conviction report
Impact
tentative
Confidence
-
AI events
2026-02-17eventPrivate placement proceeds and runway extensionHigh impact
Company closed a $12.0M private placement priced at-the-market in Feb 2026; this financing reduces near-term dilution risk and extends runway to support late-stage development/commercial activities [#PR-undated][#PR-2026-03-18].
2026-12-31catalystU.S. patent allowance and expected issuance for CTx-1301 (PTR platform)High impact
Company disclosed a Notice of Allowance for a U.S. patent covering CTx-1301 formulation/methods that, upon issuance, is expected to provide protection through May 2042; patent issuance strengthens IP around the PTR platform and supports commercialization optionality [#PR-2026-03-18].
2027-04-10catalystScale-up / manufacturing partnership execution for CTx-1301 commercializationHigh impact
Management announced an exclusive manufacturing partnership (Bend Bio Sciences) to support future commercialization of the next-generation ADHD treatment; successful scale-up and initial commercial supply agreements would be a material commercial de-risking event [#PR-undated][#PR-2026-03-18].
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-10 • Updated nightlySource: Internal modelMethodology